Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Gadolinium as the metal center
What ifWhat if the complex uses a trivalent gadolinium ion as its metal center?
Claim language“Mn, Fe, Co, Ni, and Zn”
A macrocyclic ligand binds gadolinium through four ring nitrogen atoms and four phosphonate oxygen atoms, leaving one coordination site for water. Exchange of the coordinated water with bulk water shortens the longitudinal proton relaxation time.
1.2Carboxylate at one ligand site
What ifWhat if one of the four ligand sites carries a carboxymethyl arm?
Claim language“H or —X—CH2—P(O)(OH)2”
Two phosphonomethyl arms and one carboxymethyl arm bind manganese(II) through oxygen donors. Three macrocyclic nitrogen donors complete a six-donor ligand set, and a seventh coordination site accommodates exchangeable water.
1.4Aromatic ring as a spacer
What ifWhat if a para-phenylene ring connects the ligand scaffold to a phosphonomethyl group?
Claim language“straight or branched C1-12 hydrocarbon chain”
The two para positions connect the scaffold and phosphonomethyl group through a rigid aromatic spacer. A separate donor set on the scaffold binds manganese(II), while the exposed phosphonate contributes negative charge near neutral pH.
1.5Silicon within the spacer
What ifWhat if a dimethylsilylene unit replaces one methylene unit in the spacer?
Claim language“independently replaced with —O—, —S—, —N(R*)—”
A —CH2—Si(CH3)2—CH2— segment connects the chelating scaffold to a terminal phosphonomethyl group through carbon–silicon bonds. The scaffold binds manganese(II), and the terminal phosphonate contributes anionic charge in water.
1.6Phenyl on the sulfonamide nitrogen
What ifWhat if the linker sulfonamide nitrogen bears a phenyl substituent?
Claim language“hydrogen, C1-6 alkyl, or C3-6 cycloalkyl”
A —CH2—S(O)2—N(C6H5)—CH2— segment places the phenyl group on the sulfonamide nitrogen. The macrocyclic donor set binds the metal, and the terminal phosphonate contributes negative charge in water.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Tracer imaging in porous media columns
Pack a nonmagnetic flow column with water-saturated glass beads and connect it to a syringe pump. Inject a pulse of the manganese phosphonate complex into the inlet while maintaining a constant water flow. Acquire serial longitudinal relaxation maps and use calibration scans of standards prepared in the column fluid to estimate tracer concentration and track the flow front.
Component substitution
Phosphinate arms on a manganese chelate
Use a 1,4,7-triazacyclononane ring bearing two N–CH₂–P(=O)(OH)–CH₃ arms and coordinate manganese(II) with the ring and phosphinate donors. The methyl group on each phosphorus replaces one of the two hydroxyl groups of a phosphonic acid arm. Remove unbound manganese by preparative chromatography and measure longitudinal relaxivity in buffered water using a concentration series.
Parameter or scale variation
Temperature and concentration series for relaxometry
Prepare the manganese phosphonate complex at 0, 0.10, 0.25, 0.50, and 1.00 millimolar in a common buffer. Equilibrate the samples at 20, 30, and 37 degrees Celsius and acquire inversion-recovery data at 3 tesla using inversion times from 50 to 5,000 milliseconds. At each temperature, fit the longitudinal relaxation rate against complex concentration and report the slope as longitudinal relaxivity.
Timed contrast exchange in hydrogel slabs
Cast 1, 2, and 4 millimeter agarose slabs and mount each in a chamber that exposes one face to flowing buffer. Switch the inlet from plain buffer to buffer containing 0.50 millimolar manganese phosphonate complex for 20 minutes, then switch back to plain buffer for 40 minutes. Acquire a longitudinal relaxation map every minute and use a calibration series prepared in agarose to estimate concentration as a function of depth and time.
Combination with existing systems
Flow injection coupled to magnetic resonance
Connect a six-port injection valve, a fixed-volume sample loop, and a nonmagnetic flow cell with capillary tubing. A carrier stream moves each aliquot of manganese phosphonate solution from the loop into the section of the flow cell inside the radiofrequency coil. The valve controller pauses the pump during longitudinal relaxation measurement and restarts it to flush the cell between aliquots.
Automated or data-driven variant
Automated ph fitting from resonance shifts
Acquire reference spectra of the phosphonate complex over a grid of pH values and temperatures at a fixed ionic strength. Software fits the calibrated nonexchangeable proton peak and an internal reference peak in each voxel, then interpolates pH from their frequency separation at the measured sample temperature. The software masks voxels with weak or overlapping peaks and outputs a pH map with a mask showing where the fit succeeds.
Specific version of a part
Manganese with coordinated water
A chelating ligand binds high-spin manganese(II) through nitrogen and oxygen donors. A water molecule occupies an open coordination site and exchanges with bulk water, increasing the longitudinal proton relaxation rate.
Direct phosphonomethyl attachment
A single bond connects a scaffold nitrogen directly to the methylene carbon of —CH2—P(O)(OH)2. The short arm positions a phosphonate oxygen near the metal-binding cavity.
Branched saturated carbon spacer
A —CH2—CH(CH3)—CH2— spacer connects the scaffold to the phosphonomethyl group. The branch occupies the middle carbon of the spacer, and terminal methylene groups provide the two attachment points.
Ether oxygen within the spacer
An oxygen atom replaces the central methylene of a three-position spacer to give —CH2—O—CH2—. The ether changes the spacer polarity and connects the scaffold to the terminal phosphonomethyl group through single bonds.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1each Tn is independently a divalent or trivalent transition metal ion selected from the group consisting of Mn, Fe, Co, Ni, and Zn
1.2each Y1, Y2, Y3, or Y4 is independently H or —X—CH2—P(O)(OH)2
1.3each X is independently a bond or LL
Y is hydrogen or a substituent, illustratively an electron withdrawing substituent, including but not limited to nitro, cyano, halo, alkylsulfonyl, a carboxylic acid derivative, and the like; 1s is either a bond or another bivalent linker; and where V is as defined herein.
B · US 2021/0061764 A1 · ¶
1.4each LL is independently a bivalent, saturated or unsaturated, straight or branched C1-12 hydrocarbon chain
X1 and X2 are each independently selected leaving groups; and L1 and L2 are each independently selected bivalent linkers.
B · US 2021/0061764 A1 · ¶
1.5wherein 0-6 methylene units of the hydrocarbon are independently replaced with —O—, —S—, —N(R*)—, —OC(═O)—, —C(═O)O—, —S(O)—, —S(O)2—, —N(R*)S(O)2—, —S(O)2N(R*)—, —N(R*)C(═O)—, —C(═O)N(R*)—, —OC(═O)N(R*)—, or —N(R*)C(═O)O—
1.6wherein each R* is independently hydrogen, C1-6 alkyl, or C3-6 cycloalkyl
1.7with the proviso that at least two of Y1, Y2, Y3, and Y4, if present, are independently —X—CH2—P(O)(OH)2.
A2 chelating agents include, but are not limited to, methyldiphosphonic acid, aminotri(methylenephosphonic acid), 1-hydroxyethylidene-1,1-diphosphonic acid (HEDP), ethylenediaminetetra(methylenephosphonic acid), hexamethylenediaminetetra(methylenephosphonic acid), propylenediaminetetra(methylenephosphonic acid), diethylenetriaminepenta(methylenephosphonic acid), triethylenetetraminehexa(methylenephosphonic acid), triaminotriethylaminehexa(methylenephosphonic acid), trans-1,2-
A · US 10,570,522 B2 · ¶ 31
An empty cell means only that no passage was reproduced there.
Statements in these documents
Accordingly, the need remains in the art for a solution that can selectively etch copper or copper alloy relative to nickel-containing material from a microelectronic device simultaneously including copper or copper alloy and nickel-containing material.
A · US 10,570,522 B2 · ¶ 6
The present invention generally relates to a solution that can selectively etch copper or a copper alloy at a step of etching copper or a copper alloy from a microelectronic substrate including copper or a copper alloy and nickel-containing material.
A · US 10,570,522 B2 · ¶ 7
There exists a continuing need for bivalent linkers that can be generally used in drug, vitamin, diagnostic, and imaging agent conjugates.
B · US 2021/0061764 A1 · ¶ 3
It is appreciated that multiple linkers may be used between the two or more chemical entities to change the distance between the two entities and/or to change the physicochemical properties of the conjugates prepared therefrom.
B · US 2021/0061764 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0356869 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356869/, SHA-256 95cf3994f5ed28575e3bf9ab6a3e5244777a02d06b1593b4b5dbe9b137d52313